ISRG
Intuitive Surgical, Inc.
ISRG has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over ISRG overall, supported by stronger fundamentals and stronger modeled upside.
ISRG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
ISRG's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ISRG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 36x | $440 | — |
| Cheap | 52x | $429 | -2.5% |
| Current | 53x | $440 | — |
| Fair | 72x | $596 | +36% |
| Expensive | 84x | $691 | +57% |
Historical ranges are pointers, not guarantees.
ISRG has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ISRG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| High |
Analysts expect earnings and revenue growth for ISRG, with profitability improving.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ISRG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.09 | +47% |
| Q3 2026 | $8.25 | +9% |
| Q2 2026 | $8.71 | +21% |
| Q1 2026 | $8.23 | +20% |
| Q4 2025 | $7.87 | +23% |
| Q3 2025 | $7.57 | +22% |
| Q2 2025 | $7.18 | +23% |
| Q1 2025 | $6.83 | +23% |
| Q4 2024 | $6.42 | +28% |
ISRG's earnings per share have climbed steadily: $8.25 over the past year, up 9% from the year before, and higher year over year for 14 quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ISRG on earnings, with stronger typical year-over-year growth.
ISRG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3B | +22% |
| Q2 2026 | $2.9B | +19% |
| Q1 2026 | $2.8B | +23% |
| Q4 2025 | $2.9B | +19% |
| Q3 2025 | $2.5B | +23% |
| Q2 2025 | $2.4B | +21% |
| Q1 2025 | $2.3B | +19% |
| Q4 2024 | $2.4B | +25% |
ISRG's revenue has grown year over year every quarter since late 2020: $3B last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | -11 points |
| Q2 2026 | 34% | +3.1 points |
| Q1 2026 | 31% | +5.2 points |
| Q4 2025 | 30% | -0.3 points |
| Q3 2025 | 30% | +2 points |
| Q2 2025 | 30% | +2.2 points |
| Q1 2025 | 26% | +0.8 points |
| Q4 2024 | 30% | +7.1 points |
ISRG's operating margin was 19% last quarter, down 11 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ISRG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ISRG on profitability, with a higher operating margin.
ISRG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +51% |
| Q2 2026 | $948.4M | +69% |
| Q1 2026 | $808.6M | +74% |
| Q4 2025 | $730M | +43% |
| Q3 2025 | $735.6M | +60% |
| Q2 2025 | $560.1M | +80% |
| Q1 2025 | $465M | +1879% |
| Q4 2024 | $510.6M | +$717.8M |
ISRG has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ISRG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.6% | -5.7M shares |
| 1 year | -2.8% | -10.2M shares |
| 3 years | -1.8% | -6.6M shares |
| 5 years | -4.1% | -15.2M shares |
| Available history | -1.9% | -6.9M shares |
ISRG has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3B |
| Q2 2026 | $320.3M |
| Q1 2026 | $1.1B |
| Q4 2025 | $201M |
| Q3 2025 | $1.9B |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
ISRG spent $4.6B buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ISRG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -0.6x | Net Cash |
| Q3 2021 | -0.6x | Net Cash |
| Q2 2021 | -0.9x | Net Cash |
| Q1 2021 | -1.0x | Net Cash |
| Q4 2020 | -1.2x | Net Cash |
| Q3 2020 | -1.1x | Net Cash |
| Q2 2020 | -1.5x | Net Cash |
| Q1 2020 | -0.8x | Net Cash |
ISRG has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ISRG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.7 | Neutral |
| Stochastic | 73.5 | Neutral |
ISRG's weekly RSI is 55 (neutral) and its Stochastic is 74 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ISRG PE vs Healthcare Sector
| Metric | ISRG | Sector median | Relative |
|---|---|---|---|
| PE | 53x | 26x | 106% above |
| PE % | 19 | 29 | 10 pts below |
ISRG is trading at 53x earnings, a 106% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over ISRG on valuation relative to its sector.
ISRG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $428.1 | 2.8% above |
| 20 week MA | $397.4 | 11% above |
| 50 week MA | $449.8 | 2.2% below |
| 100 week MA | $483.9 | 9.1% below |
| 200 week MA | $424.9 | 3.5% above |
ISRG's trend is mixed: it's above three of its five weekly moving averages, and 3.5% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ISRG on trend strength, trading above more of its moving averages.
ISRG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $199.3 | $269.0 | +35% |
| 2021 | $269.0 | $363.9 | +35% |
| 2022 | $363.9 | $262.7 | -28% |
| 2023 | $262.7 | $337.4 | +28% |
| 2024 | $337.4 | $534.9 | +59% |
| 2025 | $534.9 | $577.8 | +8% |
| 2026 YTD | $577.8 | $439.9 | -24% |
ISRG has finished higher in five of the last six years. It's down 24% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ISRG on returns for 2026, with the stronger performance.